Biological evaluation of N-2-hydroxypropyl trimethyl ammonium chloride chitosan as a carrier for the delivery of live Newcastle disease vaccine. (20th September 2016)

• Record Type: Journal Article
• Authors: Zhao, Kai; Sun, Yanwei; Chen, Gang; Rong, Guangyu; Kang, Hong; Jin, Zheng; Wang, Xiaohua
• Is Part Of: Carbohydrate polymers. Volume 149(2016)
• Page Start: 28
• Page End: 39
• Publication Date: 2016-09-20
• Subjects: Newcastle disease -- Live Newcastle disease vaccine -- N-2-hydroxypropyl trimethyl ammonium chloride -- Chitosan nanoparticles -- Mucosal immune delivery system -- Immune efficacy; Polysaccharides -- Periodicals; Polysaccharides -- Periodicals; Polysaccharides -- Périodiques; Electronic journals; 547.78
• DOI: 10.1016/j.carbpol.2016.04.085
• Languages: English
• ISSNs: 0144-8617

Abstract

Highlights: Newcastle disease virus encapsulated in N -2-hydroxypropyltrimethyl ammonium chloride chitosan (NDV/LaSota-N-2-HACC-NPs). In vitro release, stability and safety of the NDV/LaSota-N-2-HACC-NPs. Immune efficacy of the NDV/LaSota-N-2-HACC-NPs. A mucosal immunity delivery carrier for live Newcastle disease vaccine. Abstract: Mucosal immune system plays a very important role in antiviral immune response. We prepared Newcastle disease viruses (NDV) encapsulated in N -2-hydroxypropyl trimethyl ammonium chloride chitosan (N-2-HACC) nanoparticles (NDV/La Sota-N-2-HACC-NPs) by an ionic cross linking method, and assessed the potential of N-2-HACC-NPs as a mucosal immune delivery carrier. The properties of the nanoparticles were determined by transmission electron microscopy, Zeta potential and particle size analysis, encapsulation efficiency and loading capacity. NDV/La Sota-N-2-HACC-NPs have regular spherical morphologies and high stability; with 303.88 ± 49.8 nm mean diameter, 45.77 ± 0.75 mV Zeta potential, 94.26 ± 0.42% encapsulation efficiency and 54.06 ± 0.21% loading capacity. In vitro release assay indicated that the release of NDV from NDV/La Sota-N-2-HACC-NPs is slow. The NDV/La Sota-N-2-HACC-NPs have good biological characteristics, very low toxicity and high level of safety. Additionally, specific pathogen-free chickens immunized with NDV/La Sota-N-2-HACC-NPs showed much stronger cellular, humoral and mucosal immune responses than commercial attenuated live Newcastle disease vaccine, and NDV/La Sota-N-2-HACC-NPs reached the sustainable release effect. Our study here provides a foundation for the further development of mucosal vaccines and drugs, and the N-2-HACC-NPs should be a potential drug delivery carrier with immense potential in medical applications.